Nebokitug reduces immune cell activity that drives PSC: Data
Nebokitug, an experimental infusion therapy being developed by Chemomab Therapeutics for primary sclerosing cholangitis (PSC), reduces the inflammatory…
Cholangitis
New trial testing probiotic for reducing liver inflammation in PSC
Liscure Biosciences has launched a Phase 2 clinical trial to test whether its experimental probiotic LB-P8 can improve gut health and reduce liver inflammation…
Livdelzi maintains benefits for up to 3 years in PBC: Phase 3 data
Up to three years of treatment with Gilead Sciences‘ Livdelzi (seladelpar) results in sustained reductions in itching and biomarkers of liver injury in adults…
Most recent liver stiffness test best predicts risk of PBC progression
The most recent assessment of liver stiffness best predicts the future risk of liver disease progression among adults with primary biliary cholangitis (PBC), regardless…
This year, it’s ‘hope into action’ for PSC Awareness Day
Oct. 29 is Global PSC Awareness Day, and advocates around the world are joining forces to shine a light on primary sclerosing cholangitis (PSC)…
Potential biliary atresia treatment AX-0810 to enter clinical testing
AX-0810, an experimental medication Proqr Therapeutics is developing for biliary atresia and another liver disease called primary sclerosing cholangitis (PSC), is about to…
Seladelpar approved in Canada as Lyvdelzi to treat adults with PBC
Health Canada has conditionally approved Gilead Sciences’ seladelpar — to be marketed in the country under the brand name Lyvdelzi — as a second-line…
Women with PBC may be at high risk of disease flares after childbirth
Women with primary biliary cholangitis (PBC) may be at increased risk of having disease flares in the months following childbirth, according to a small…
Liver Foundation honors family who turned diagnosis into giving
A family whose experience with biliary atresia led to an effort to help others navigate the challenges of pediatric liver disease is among those being…
Aramchol shows promise as PSC treatment, mouse study finds
Aramchol, a small molecule in the Galmed Pharmaceuticals pipeline, prevented and reversed inflammation and scarring (fibrosis) of the bile ducts in mouse models of…
Recent Posts
- Nebokitug reduces immune cell activity that drives PSC: Data
- New biomarkers may help detect pregnancy-linked liver complication
- Access to food is a survival tactic when your liver needs nutrition
- Belapectin may help reduce liver scarring in those with severe MASH
- Parents and son are all on a path of discovery with Alagille syndrome